Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
Cart
Search
nav search
Search
Toggle MenuMenu
Skip Nav Destination

Literature Scan

New and noteworthy research from the medical literature landscape
Enasidenib Plus Azacitidine Combo Improved Response Rates in Newly Diagnosed IDH2-mutated AML
Researchers Identify Specific Genetic Abnormalities Predictive of Myeloid and Lymphoid Malignancies
Corticosteroids Increase the Risk of Recurrent Thrombotic Events
Analyzing Survival Outcomes With Ixazomib-Rd in Relapsed/Refractory Multiple Myeloma
Reduced Intensity Conditioning Transplantation Confers Survival Advantage Over Chemo in Older Patients With AML
Therapeutic Heparin May Benefit Moderately Ill, Hospitalized Patients With COVID-19
Daratumumab Maintenance Improves PFS in Newly Diagnosed Myeloma
Frontline, Time-Limited Acalabrutinib, Venetoclax, and Obinutuzumab Active in Treatment-Naïve CLL
Mycophenolate Mofetil Plus Glucocorticoid Reduces Relapse Risk in ITP
Anemia, Inflammation Associated With Worse Outcomes in Patients With Coronary Artery Disease
Evaluating a Machine Learning Approach for the Detection of AML
New Prognostic Model Outperforms Established Predictive Models in MDS
Ixazomib-Based Regimen Induces Responses in Heavily Pretreated Waldenström Macroglobulinemia
Teclistamab Demonstrates Promising Efficacy, Safety in Relapsed/Refractory Multiple Myeloma
Low-Pressure Compression Garments Helpful for Pediatric Post-Thrombotic Syndrome
Reduced-Intensity Conditioning Transplant Superior to Continuous 5-Azacitidine in Older-Patients With MDS
Reduced-Intensity Conditioning Transplant Superior to Continuous 5-Azacitidine in Older Patients With MDS
Show more items from this collection

Advertisement

  CURRENT ISSUE
  Mid-January 2022

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright ©2022 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement

X